The Genesis Framework: A Systems-Control Architecture for Safe Partial Cellular Rejuvenation via Stoichiometric saRNA Delivery, Integrated miRNA Logic Gating, and SORT Lipid Nanoparticles

Abstract

BackgroundThe twelve hallmarks of aging as defined by Lopez-Otin et al. (Cell, 2023) represent the primary, antagonistic, and integrative mechanisms driving biological aging. To our knowledge, no open-source preclinical framework has yet attempted to coordinate all 12 official hallmarks in a single modular, non-integrating, safety-gated design validated across tens of thousands of computational cycles. This manuscript presents The Cepeda Framework -- a modular, safety-first preclinical research program designed to test whether coordinated partial rejuvenation strategies can be pursued in a falsifiable and systematically safety-constrained manner. Computational DevelopmentThe framework was developed through 21,000 dual-validation simulation cycles -- each simultaneously testing Efficacy (epigenetic reversal) and Safety (NANOG induction prevention) -- executed by the Forward Thinking Communities Scientific Group over one year of intensive computational modeling. The program evolved through four distinct phases: from the original Genesis Framework single-hallmark concept (Cycles 1-5,000; FAILURE -- 1:1:1 ratio unsafe), through stoichiometric ratio optimization (Cycles 5,001-12,000; PIVOT -- 3:2:1 ratio locked), gate verification (Cycles 12,001-18,000; SUCCESS -- dual-miRNA logic validated), and final 12-hallmark integration (Cycles 18,001-21,000; CONVERGENCE -- Cepeda Framework finalized). FrameworkThe Cepeda Framework integrates five regulatory principles -- (I) stoichiometric 3:2:1 OCT4:SOX2:KLF4 polycistronic m1{Psi}-saRNA; (II) 72-hour intrinsic saRNA pulse; (III) LEAD-7294 dual-miRNA logic gate (kill-switch + Let-7/L7Ae/Kt activation gate); (IV) NRF2/NAD+/paracrine microenvironmental co-treatment; (V) Genesis-TERT-01 transient hTERT telomere restoration -- with five companion protocols (Rapamycin pulse, Metformin, AP39 H2S donor [HIGH-UNCERTAINTY; Tier 1A required], GGA/4-PBA proteostasis stack, and Akkermansia/synbiotic/butyrate dysbiosis correction). Together, these components map to all 12 official Lopez-Otin 2023 hallmarks plus one Copenhagen 2022 candidate hallmark (RNA splicing dysregulation). SafetyNine parallel and sequential safety safeguards ensure no single-point failure produces uncontrolled reprogramming or sustained exposure, including the embedded LEAD-7294 miR-294 kill-switch (predicted t[1/2] <12 min at >5,000 copies/cell), the proactive Let-7/L7Ae/Kt activation gate, intrinsic saRNA transience, the 3:2:1 stoichiometric brake, and a predefined Acute Cytokine Response (ACR) monitoring protocol. All companion agents are clinically approved or have established in vitro/in vivo safety profiles. StatusTheoretical preclinical framework. No wet-laboratory validation of the integrated protocol has been conducted. All quantitative predictions require experimental falsification. Validation proceeds through a five-tier modular preclinical roadmap beginning with aged human dermal fibroblasts. All simulation code and archives will be released under CC0 at or before preprint submission.